Document Type : Original Article


1 Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.

2 Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran

3 Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Khomein University of Medical Sciences, Khomein, Iran

5 Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, ‎Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

6 Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran


Background: A lot of patients are suffering from asthma. For decreasing the asthma symptoms, we studied the effects of conditioned medium (CM) of human amniotic membrane mesenchymal stem cells (hAM-MSCs) as a source of anti-inflammatory cytokines on splenocyte and lung tissue of asthmatic Balb/c mice.
Methods: Forty mice were categorized into four groups; ovalbumin (OVA)-induced asthma, CM-treated asthma, DMEM (Dulbecco's Modified Eagle Medium)-treated asthma, and saline control. Each group received related treatment. The lung alpha-smooth muscle actin (α-SMA)  and splenocyte inflammatory cytokines and IgE were examined through Western blot analysis.
Results: Western blot showed α-SMA overexpression in the OVA and DMEM groups compared with the saline group. CM therapy could significantly reverse it compared with OVA and OVA+DMEM categories by elevating IL-10 and IFN-γ and reducing IL-4, IgE, and TGF-β .
Conclusion: CM treatment could improve asthma symptoms by adjusting α-SMA in lung tissue and pro-inflammatory cytokines and IgE in splenocytes.


Main Subjects

1.Côté A, Godbout K, Boulet L-P. The management of severe asthma in 2020. Biochemical Pharmacology. 2020:114112.
2.Mims JW. Asthma: definitions and pathophysiology. Paper presented at: International forum of allergy & rhinology, 2015.
3.Meng-Jie Feng FS, Chen Qiu ⁎, Wen-Ke Peng. MicroRNA-181a, -146a and -146b in spleen CD4+ T lymphocytes play proinflammatory roles in a murine model of asthma. International Immunopharmacology. 2012;13:347–353.
4.Lv X, Gao Z, Tang W, Qin J, Wang W, Liu J, Li M, Teng F, Yi L, Dong J. Trends of therapy in the treatment of asthma. Therapeutic Advances in Respiratory Disease. 2023;17:17534666231155748.
5.Yun X, Shang Y, Li M. Effect of Lactobacillus salivarius on Th1/Th2 cytokines and the number of spleen CD4+ CD25+ Foxp3+ Treg in asthma Balb/c mouse. International journal of clinical and experimental pathology. 2015;8(7):7661.
6.Li N, Dong X, Yang C, Liu Y, Ni X. Expression of neuronal protein Kidins220/ARMS in the spleen and peripheral blood of mice following airway allergen challenge. Molecular medicine reports. 2013;8(6):1871-1875.
7.Carpaij OA, Burgess JK, Kerstjens HA, Nawijn MC, van den Berge M. A review on the pathophysiology of asthma remission. Pharmacology & therapeutics. 2019;201:8-24.
8.Koopmans T, Hesse L, Nawijn MC, Kumawat K, Menzen MH, Bos IST, Smits R, Bakker ER, Van Den Berge M, Koppelman GH. Smooth-muscle-derived WNT5A augments allergen-induced airway remodelling and Th2 type inflammation. Scientific reports. 2020;10(1):1-14.
9.Kumawat K, Koopmans T, Menzen MH, Prins A, Smit M, Halayko AJ, Gosens R. Cooperative signaling by TGF-β1 and WNT-11 drives sm-α-actin expression in smooth muscle via Rho kinase-actin-MRTF-A signaling. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2016;311(3):L529-L537.
10.Cherng S, Young J, Ma H. Alpha-smooth muscle actin (α-SMA). The Journal of American Science. 2008;4(4):7-9.
11.Ramos-Barbón D, Fraga-Iriso R, Brienza NS, Montero-Martínez C, Verea-Hernando H, Olivenstein R, Lemiere C, Ernst P, Hamid QA, Martin JG. T cells localize with proliferating smooth muscle α-actin+ cell compartments in asthma. American journal of respiratory and critical care medicine. 2010;182(3):317-324.
12.Toyoshima S, Wakamatsu E, Ishida Y, Obata Y, Kurashima Y, Kiyono H, Abe R. The spleen is the site where mast cells are induced in the development of food allergy. International immunology. 2017;29(1):31-45.
13.Zhao X, Chen T, Meng F, Wang H, Tian P, Tang X, Wang X, Wang X, Xin H, Wei H. Therapeutic effect of herb residue fermentation supernatant on spleen‑deficient mice. Molecular medicine reports. 2018;17(2):2764-2770.
14.Jafari A, Niknejad H, Rezaei-Tavirani M, Sarrami-Forooshani R, Gilanchi S, Jafari Z. Antiproliferative and apoptotic effects of conditioned medium released from human amniotic epithelial stem cells on breast and cervical cancer cells. International Journal of Immunopathology and Pharmacology. 2023;37:03946320221150712.
15.Calonge M. Amniotic membrane as a substrate and delivery vehicle for stem cells. Acta Ophthalmologica. 2022;100.
16.Luan Y, Kong X, Feng Y. Mesenchymal stem cells therapy for acute liver failure: recent advances and future perspectives. Liver Research. 2021;5(2):53-61.
17.Tousi SMTR, Amirizadeh N, Nasirinezhad F, Nikougoftar M, Ganjibakhsh M, Aboutaleb N. A rapid and cost-effective protocol for isolating mesenchymal stem cells from the human amniotic membrane. Galen Medical Journal. 2017;6(3):217-225.
18.Pawitan JA. Prospect of stem cell conditioned medium in regenerative medicine. BioMed research international. 2014;2014.
19.Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. Allergy, Asthma & Clinical Immunology. 2020;16:1-11.
20.Aboutaleb N, Faezi M, Maleki SN, Nazarinia D, Tousi SMTR, Hashemirad N. Conditioned medium obtained from mesenchymal stem cells attenuates focal cerebral ischemia reperfusion injury through activation of ERK1/ERK2-BDNF signaling pathway. Journal of chemical neuroanatomy. 2019;97:87-98.
21.Faezi M, Maleki SN, Aboutaleb N, Nikougoftar M. The membrane mesenchymal stem cell derived conditioned medium exerts neuroprotection against focal cerebral ischemia by targeting apoptosis. Journal of chemical neuroanatomy. 2018;94:21-31.
22.Dalouchi F, Falak R, Bakhshesh M, Sharifiaghdam Z, Azizi Y, Aboutaleb N. Human amniotic membrane mesenchymal stem cell‐conditioned medium reduces inflammatory factors and fibrosis in ovalbumin‐induced asthma in mice. Experimental Physiology. 2021;106(2):544-554.
23.Shinde AV, Humeres C, Frangogiannis NG. The role of α-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(1):298-309.
24.Nam Y, Lee S, Sammut D, Davies D, Howarth P. Preliminary study of the cellular characteristics of primary bronchial fibroblasts in patients with asthma: expression of alpha-smooth muscle actin, fibronectin containing extra type III domain A, and smoothelin. Journal of investigational allergology & clinical immunology. 2012;22(1):20-27.
25.Sun K-H, Chang Y, Reed NI, Sheppard D. α-Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGFβ activation or collagen production across multiple models of organ fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2016;310(9):L824-L836.
26.Liu D, Gong L, Zhu H, Pu S, Wu Y, Zhang W, Huang G. Curcumin inhibits transforming growth factor β induced differentiation of mouse lung fibroblasts to myofibroblasts. Frontiers in pharmacology. 2016;7:419.
27.Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Molecular biology of the cell. 2001;12(9):2730-2741.
28.Minshawi F, Lanvermann S, McKenzie E, Jeffery R, Couper K, Papoutsopoulou S, Roers A, Muller W. The generation of an engineered interleukin-10 protein with improved stability and biological function. Frontiers in immunology. 2020;11:1794.
29.Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunologic research. 2010;47:185-206.
30.Hou C, Sun F, Liang Y, Nasab EM, Athari SS. Effect of transduced mesenchymal stem cells with IL-10 gene on control of allergic asthma. Allergologia et Immunopathologia. 2023;51(2):45-51.
31.Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. Journal of Allergy and Clinical Immunology. 2023.
32.Fujita H, Teng A, Nozawa R, Takamoto-Matsui Y, Katagiri-Matsumura H, Ikezawa Z, Ishii Y. Production of both IL-27 and IFN-γ after the treatment with a ligand for invariant NK T cells is responsible for the suppression of TH2 response and allergic inflammation in a mouse experimental asthma model. The Journal of Immunology. 2009;183(1):254-260.
33.Gauvreau GM, Bergeron C, Boulet LP, Cockcroft DW, Cote A, Davis BE, Leigh R, Myers I, O'Byrne PM, Sehmi R. Sounding the alarmins—The role of alarmin cytokines in asthma. Allergy. 2023;78(2):402-417.
34.Mosayebi G, Moazzeni SM. Spleen and liver dendritic cells differ in their tolerogenic and cytokine induction potential. The Iranian Journal of Allergy, Asthma and Immunology. 2011.
35.Dai R, Yu Y, Yan G, Hou X, Ni Y, Shi G. Intratracheal administration of adipose derived mesenchymal stem cells alleviates chronic asthma in a mouse model. BMC pulmonary medicine. 2018;18(1):1-9.
36.Wei Y, Luo Q-L, Sun J, Chen M-X, Liu F, Dong J-C. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. Journal of ethnopharmacology. 2015;164:368-377.
37.Kianmehr M, Haghmorad D, Nosratabadi R, Rezaei A, Alavinezhad A, Boskabady MH. The effect of Zataria multiflora on Th1/Th2 and Th17/T regulatory in a mouse model of allergic asthma. Frontiers in pharmacology. 2017;8:458.
38.Mohseni MM, Amani J, Ramandi MF, Mahjoubi F, Jafari M, Salmanian AH. Immunogenicity evaluation of recombinant edible vaccine candidate containing HER2-MUC1 against breast cancer. Iranian Journal of Allergy, Asthma and Immunology. 2019;18(5):511-522.
39.Cazzola M, Polosa R. Anti-TNF-α and Th1 cytokine-directed therapies for the treatment of asthma. Current opinion in allergy and clinical immunology. 2006;6(1):43-50.
40.Huang B, Cheng X, Wang H, Huang W, Wang D, Zhang K, Zhang H, Xue Z, Da Y, Zhang N. Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively. Journal of translational medicine. 2016;14(1):1-12.